Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06250842
Other study ID # PJ-KS-KY-2023-577
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 11, 2024
Est. completion date June 30, 2026

Study information

Verified date January 2024
Source The First Affiliated Hospital of Dalian Medical University
Contact Hui min Zhang
Phone +86 18098876233
Email huiminzhangxs@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study explores the impact of long-term benzodiazepine (BZDs) use on cognitive function and associated neuroimaging markers. While BZDs are established treatments for conditions like anxiety and insomnia, recent warnings highlight risks, including neurocognitive effects. Neuroimaging studies indicate potential neuroprotective effects of BZDs. Functional near-infrared spectroscopy (fNIRS) measures cerebral cortex function during cognitive tasks. Combining fNIRS with mood and cognitive scales, this study assesses cortical activation. 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) evaluates brain metabolism. DPA-714 PET assesses neuroinflammation. The primary objective is to compare brain functional activation, metabolism, and neuroinflammatory levels between long-term BZD users and non-users. This comprehensive approach aims to provide insights into BZD effects on cognition and associated brain markers.


Description:

Benzodiazepines(BZDs) have been long-established treatments for various conditions, including anxiety disorders and insomnia. Recent FDA warnings emphasize the risks of misuse and dependence associated with BZDs. Epidemiological investigations have consistently raised concerns regarding the long-term utilization of GABAergic medications, such as BZD and Z-drugs, due to their observed association with an elevated likelihood of neurocognitive impairments, including the development of Alzheimer's disease(AD). Recent neuroimaging studies have provided insights into the neuroprotective effects of BZD. These studies reveal that prolonged use of BZD in humans is associated with reduced amyloid deposition and a greater hippocampus volume. Functional near-infrared spectroscopic imaging utilizes changes in measured near-infrared light to monitor relative changes in oxyhemoglobin and deoxyhemoglobin concentrations in the cerebral cortex, allowing the detection of dynamic changes in cerebral cortical function during cognitive processing states. In this study, investigators will use functional near-infrared spectroscopy (fNIRS) to measure oxygenated (HbO2), deoxygenated hemoglobin (HbR), and total hemoglobin activation in various parts of the cortex, combined with mood and cognitive scales. Brain metabolism, measured using 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) imaging, can guide clinicians in both research and clinical evaluation, with specific patterns of brain metabolism reduction aiding in the diagnosis of AD or related disorders. The PET tracer DPA-714, binding to the 18 kDa translocator protein (TSPO), provides a non-invasive measure of neuroinflammation in activated microglia/macrophages within the mitochondria. The primary objective of this study is to observe differences in brain functional activation, brain metabolism, and brain neuroinflammatory levels between subjects on long-term BZDs use and those not taking BZDs.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 30, 2026
Est. primary completion date February 20, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Continuous use of benzodiazepines for =3 months, matched with participants who have not taken benzodiazepines. 2. Education time =6 years. 3. Abstained from alcohol, coffee, and other psychoactive substances in the 24 hours before the examination. Exclusion Criteria: 1. Brain damage due to various reasons (such as head trauma, dementia, epilepsy, brain tumors, etc.). 2. Severe systemic diseases (such as malignant tumors, etc.). 3. Acute cerebrovascular disease in the past 3 months. History of substance abuse other than benzodiazepines (such as alcohol, opioids, etc.). 4. Inability to cooperate with fNIRS, PET/MRI examinations, and scale assessments.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China The First Affiliated Hospital of Dalian Medical University Dalian Liaoning

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Dalian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain hemodynamic activity with fNIRS This includes changes in the concentration of oxygenated and deoxygenated hemoglobin as measured by the change in light absorption. for 2 years
Primary Longitudinal evolution of biomarkers measured from structural neuroimaging (MRI) and molecular neuroimaging (18F-FDG PET/MRI?DPA-714-PET/MRI) Estimates of brain TSPO concentrations measured with PET will serve as a marker for neuroinflammation. Variation of the regional cerebral glucose consumption and TSPO-PET measures will be compared between three groups. for 2 years
Secondary Mini-Mental State Evaluation (MMSE) Clinician-administered screening tool used to systematically and thoroughly assess mental status through five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. Scores range between 0-30. A score of 25 or higher is classed as normal. If the score is below 24, the result is usually considered to be abnormal, indicating possible cognitive impairment. About 15 min during the study visit
Secondary Scores of Hamilton Depression Scale Using to assess depressive symptoms. With higher scores associated with more severe depression symptoms. Total scores <7 is normal; Mild depression with total scores of 7~17; Moderate depression with total scores of 18~24; Total scores >24 for severe depression. About 15 min during the study visit
Secondary Scores of Hamilton Anxiety Scale Using to assess anxiety symptoms. With higher scores associated with more severe anxiety symptoms. Total scores< 7 indicates no anxiety; Total scores=7 indicates possible anxiety; Total scores=14 indicates anxiety; Total scores=21 indicates obvious anxiety; Total scores=29 points indicates serious anxiety. About 15 min during the study visit
Secondary Pittsburgh Sleep Quality Index Using to assess the sleep quality. Total scores of 0-5 indicates that the quality of sleep is very good, 6~10 indicates that the quality of sleep is OK, 11~15 indicates that the quality of sleep is average, and 16~21 indicates that the quality of sleep is poor. About 15 min during the study visit
See also
  Status Clinical Trial Phase
Completed NCT04122482 - An Online Course for Improving Knowledge and Access to Mental Health Accommodations in Canadian Enterprises N/A
Completed NCT04085861 - Mental Health in Dancers; an Intervention Study N/A
Recruiting NCT06060210 - Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion Phase 4
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Recruiting NCT06065787 - NeuroGlove Anxiety and Depression Study N/A
Active, not recruiting NCT04583891 - Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design N/A
Completed NCT05554042 - Kintsugi Voice Device Study
Not yet recruiting NCT06430853 - Psychobiological Interventions in Pregnancy N/A
Not yet recruiting NCT06162624 - Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons N/A
Completed NCT02954250 - Mindfulness Based Cognitive Therapy for Depression and Cognitive Inhibition in Suicide Early Phase 1
Recruiting NCT05647499 - Evaluating the Back 2 School Program in a Norwegian Setting: A Multicenter Pilot Study N/A
Completed NCT03980873 - Cognitive-Behavioral Therapy for Young Adult Lesbian, Gay and Bisexual: Transdiagnostic Minority Stress Approach N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Completed NCT05368155 - Chronic Pelvic Pain and Education Skills Training for Women Veterans N/A
Completed NCT05455905 - Voice Biomarkers Predictive of Depression and Anxiety
Completed NCT03272516 - Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients N/A
Not yet recruiting NCT05493865 - Parent-Child Single-Session Growth Mindset Intervention on Adolescent Depression and Anxiety Problems N/A
Not yet recruiting NCT06027047 - Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)
Not yet recruiting NCT05535101 - Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder N/A
Recruiting NCT04418115 - Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option? N/A